LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Schmitt, Matthias
Languages: English
Types: Doctoral thesis
Subjects: R1

Classified by OpenAIRE into

mesheuropmc: hormones, hormone substitutes, and hormone antagonists
The effects of natriuretic peptides on vascular control were investigated. In the major part of this thesis emphasis is placed on the effects of natriuretic peptides, in particular ANP, on regulation of regional vascular volume and venous tone in healthy volunteers (Chapter 3) and patients with chronic heart failure (Chapter 4). The second part of this thesis investigates the effects and mechanisms of action of ANP, BNP and CNP on large artery function in an ovine hind limb model (Chapter 5). Finally, the actions of the latest members of the natriuretic peptide family, namely DNP and NNP are investigated in vitro using rings of rabbit aorta in organ bath experiments (Chapter 6). The important new findings of this thesis are 1. ANP regulates regional vascular volume and venous tone over a wide range of physiological and pathophysiological plasma levels without affecting compliance. 2. Most importantly, basal ANP plasma levels contribute significantly to regulation of resting vascular tone. 3. The rank order of potency of NP in the forearm capacitance vasculature of patients with chronic heart failure is ANP BNP>CNP/Urodilatin. 4. Venous ANP responsiveness is preserved in patients with chronic heart failure despite marked impairment in the resistance vasculature. This preservation may be due to preserved venous endothelial function. 5. ANP acting locally modifies pulse wave velocity via the NPRa receptor. Neither CNP (acting via the NPRb receptor) nor cANF (acting via NPRc) elicit any immediate vasoactive effects. 6. Novel natriuretic peptide (NNP), a newly isolated NP from the venom of the green mamba snake (Dendroaspis angusepticus) has arterial vasorelaxant properties similar to those of ANP and DNP.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • M e th o d s ...............................................................................................161 Haemodynamic measurements.................................................................................. 162 Drugs...........................................................................................................................164 Protocol / Surgical preparation................................................................................. 164 5.3.
    • Discussion........................................................................................... 177 The effect of ANP and BNP on large conduit arteries..............................................177 CNP - a vasoactive NP?..............................................................................................178 Effects of Basal ANP plasma levelson large artery distensibility............................ 179 Clinical considerations................................................................................................ 180 Limitations.................................................................................................................. 180 5.6.
    • CHAPTER 6 - THE EFFECTS OF NOVEL NATRIURETIC PEPTIDES (NNP / DNP) ON ISOLATED RINGS OF RABBIT AORTA; COMPARISON TO ANP AND D N P ........................................................................................................ 183 6.1.
    • M eth o d s ................................................................................................ 184 Isometric Tension Recordings................................................................................... 185 Drugs and Chemicals................................................................................................. 187 Statistical analysis....................................................................................................... 188 R esults.................................................................................................. 188 Comparative ANP, DNP, NNP dose response study.................................................188 The Effects of Nitric Oxide (NO) in NNP induced vasorelaxation.......................... 190 The Effects of Prostaglandins in NNP-induced vasorelaxation.............................. 191 The Effects of sGC in NNP-induced vasorelaxation.................................................192 The Effects of NPRa-NNP interaction on vascular smooth muscle tone................193 The Effects of NPRc-NNP interaction on vascular smooth muscle tone ...............196 6.4.
    • 393. Mills RM, LeJemtel TH, Horton DP et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol 1999;34:155-62.
    • 394. Colucci WS, Elkayam U, Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment o f decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246-53.
    • 395. Burger AJ, Elkayam U, Neibaur MT et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol 2001;88:35-9.
    • 396. Burger AJ, Horton DP, LeJemtel T et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J 2002; 144:1102-8.
    • 398. Yoshimura M, Yasue H, Morita E et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1991;84:1581-8.
    • 399. Abraham WT, Lowes BD, Ferguson DA et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady- state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998;4:37-44.
    • 400. Corti R, Bumett JC, Jr., Rouleau JL, Ruschitzka F, Luscher TF. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circidation 2001;104:1856-62.
    • 401. Sagnella GA. Vasopeptidase inhibitors. J Renin Angiotensin Aldosterone Syst 2002;3:90-5.
    • 402. Dawson A, Struthers AD. Vasopeptidase inhibitors in heart failure. J Renin Angiotensin Aldosterone Syst 2002;3:156-9.
    • 403. Trippodo NC, Fox M, Natarajan V, Panchal BC, Dorso CR, Asaad MM. Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure. J Pharmacol Exp Ther 1993;267:108-16.
    • 404. Trippodo NC, Gabel RA, Harvey CM, Asaad MM, Rogers WL. Heart failure augments the cardiovascular and renal effects of neutral endopeptidase inhibition in rats. J Cardiovasc Pharmacol 1991;18:308-16.
    • 405. Trippodo NC, Robl JA, Asaad MM et al. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther 1995;275:745-52.
    • 406. Trippodo NC, Fox M, Monticello TM, Panchal BC, Asaad MM. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol 1999;34:782-90.
    • 407. Chen HH, Lainchbury JG, Matsuda Y, Harty GJ, Bumett JC, Jr. Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure. Hypertension 2001;38:187-91.
    • 408. Cataliotti A, Boerrigter G, Chen HH et al. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure. Circulation 2002;105:639-44.
    • 409. Chen HH, Cataliotti A, Bumett JC, Jr. Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: insights from experimental heart failure. Curr Hypertens Rep 2001;3 Suppl 2:815-821.
    • 410. French JF, Flynn GA, Giroux EL et al. Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase. J Pharmacol Exp Ther 1994;268:180-6.
    • 411. Raut R, Rouleau JL, Blais C, Jr. et al. Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11. Am J Physiol 1999;276:H1769-H1779.
    • 414. McClean DR, Ikram H, Garlick AH, Richards AM, Nicholls MG, Crozier IG. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol 2000;36:479-86.
    • 415. Rouleau JL, Pfeffer MA, Stewart DJ et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000;356:615- 20.
    • 416. McClean DR, Ikram H, Mehta S et al. Vasopeptidase inhibition with Omapatrilat in chronic heart failure: Acute and long-term hemodynamic and neurohormonal effects. J Am Coll Cardiol 2002;39:2034-41.
    • 417. Coats AJ. Omapatrilat - the story o f Overture and Octave. Int J Cardiol 2002;86:1-4.
    • 418. Seymour AA, Asaad MM, Abboa-Offei BE, Rovnyak PL, Fennell S, Rogers WL. Potentiation of brain natriuretic peptides by SQ 28,603, an inhibitor of neutral endopeptidase 3.4.24.11, in monkeys and rats. J Pharmacol Exp Ther 1992;262:60-70.
    • 419. Seymour AA, Abboa-Offei BE, Smith PL, Mathers PD, Asaad MM, Rogers WL. Potentiation of natriuretic peptides by neutral endopeptidase inhibitors. Clin Exp Pharmacol Physiol 1995;22:63-9.
    • 420. Rademaker MX, Charles CJ, Cooper GJ et al. Combined endopeptidase inhibition and adrenomedullin in sheep with experimental heart failure. Hypertension 2002;39:93-8.
    • 421. Chen HH, Grantham JA, Schirger JA, Jougasaki M, Redfield MM, Burnett JC, Jr. Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J Am Coll Cardiol 2000;36:1706-12.
    • 422. Chen HH, Lainchbury JG, Harty GJ, Burnett JC, Jr. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain
    • 423. Dcenouchi H, Sato H, Hirata Y, lizuka M, Serizawa T, Sugimoto T. Lack of venodilative activity of alpha human atrial natriuretic polypeptide in patients with congestive heart failure. Jpn Heart J 1989;30:443-57.
    • 424. Tsunoda K, Mendelsohn FA, Sexton PM, Chai SY, Hodsman GP, Johnston CL Decreased atrial natriuretic peptide binding in renal medulla in rats with chronic heart failure. Circ Res 1988;62:155-61.
    • 425. Tsutamoto T, Kanamori T, Morigami N, Sugimoto Y, Yamaoka O, Kinoshita M. Possibility o f downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure. Circulation 1993;87:70-5.
    • Circulation 1993;88:1016-20.
    • 427. Matsukawa N, Grzesik WJ, Takahashi N et al. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci U S A 1999;96:7403-8.
    • 428. Naruko T, Ueda M, Haze K. Natriuretic Peptide Receptor Expression in Human Failing Hearts, [abstr]. Circulation 1997;96 (Suppl I).
    • 429. Andreassi MG, Del Ry S, Palmieri C, Clerico A, Biagini A, Giannessi D. Upregulation of'clearance' receptors in patients with chronic heart failure: a possible explanation for the resistance to biological effects o f cardiac natriuretic hormones. Eur J Heart Fail 2001;3:407-14.
    • 430. Schif&in EL. Decreased density o f binding sites for atrial natriuretic peptide on platelets of patients with severe congestive heart failure. Clin Sci (Colch) 1988;74:213-8.
    • 431. Suzuki N, Shimomura H, Radany EW et al. A peptide associated with eggs causes a mobility shift in a major plasma membrane protein of spermatozoa. J Biol Chem 1984;259:14874-9.
    • Ward GE, Garbers DL, Vacquier VD. Effects o f extracellular egg factors on sperm guanylate cyclase. Science 1985;227:768-70.
    • 434. Potter LR, Garbers DL. Protein kinase C-dependent desensitization of the atrial natriuretic peptide receptor is mediated by dephosphorylation. J Biol Chem 1994;269:14636-42.
    • 435. Hussain MB and MacAllister RJ, Hobbs AJ. Reciprocal regulation of cGMPmediated vasorelaxation by soluble and particulate guanylate cyclases. Am J Physiol Heart Circ Physiol 280, HI 151-Hl 159. 2001.
    • 436. Wennberg PW, Miller VM, Rabelink T, Burnett JC, Jr. Further attenuation of endothelium-dependent relaxation imparted by natriuretic peptide receptor antagonism. Am J Physiol 1999;277:H1618-H1621.
    • 437. Nightingale AK, Blackman DJ, Ellis GR et al. Preservation of venous endothelial function in the forearm venous capacitance bed of patients with chronic heart failure despite arterial endothelial dysfunction. J Am Coll Cardiol 2001;37:1062-8.
    • 438. Riegger GA, Eisner D, Kromer EP et al. Atrial natriuretic peptide in congestive heart failure in the dog: plasma levels, cyclic guanosine monophosphate, ultrastructure of atrial myoendocrine cells, and hemodynamic, hormonal, and renal effects. Circulation 1988;77:398-406.
    • 439. Knecht M, Pagel I, Langenickel T et al. Increased expression of renal neutral endopeptidase in severe heart failure. Life Sci 2002;71:2701-12.
    • 440. Charloux A, Piquard F, Doutreleau S, Brandenberger G, Geny B. Mechanisms of renal hyporesponsiveness to ANP in heart failure. Eur J Clin Invest 2003;33:769-78.
    • 441. von Geldem TW, Rockway TW, Davidsen SK et al. Small atrial natriuretic peptide analogues: design, synthesis, and structural requirements for guanylate cyclase activation. J Med Chem 1992;35:808-16.
    • 442. Eisner D, Kromer EP, Riegger GA. Hemodynamic, renal, and hormonal effects of 8-Br-cyclic GMP in conscious dogs with and without congestive heart failure. J Cardiovasc Pharmacol 1989;14:241-7.
    • 443. Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996;2:47-54.
    • 445. Granger JP, Burnett JC, Jr., Romero JC, Opgenorth TJ, Salazar J, Joyce M. Elevated levels of atrial natriuretic peptide during aldosterone escape. Am J Physiol 1987;252:R878-R882.
    • 446. Tesar V, Spicak J, Horky K et al. [Renal resistance to atrial natriuretic factor as a cause of the escape failure phenomenon in patients with non-ascitic liver cirrhosis]. Cas Lek Cesk 1994;133:111-5.
    • 447. John SWM, Krege JH, Oliver PM et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 1995;267:679-81.
    • 448. John SWM, Veress AT, Honrath U et al. Blood pressure and fluid-electrolyte balance in mice with reduced or absent ANP. Am J Physiol 1996;271:R109- R114.
    • 449. Ablad B, Mellander S. Comparative effects of hydralazine, sodium nitrate, and acetylcholine on resistance and capacitance blood vessels and capillary filtration on skeletal muscle in the cat. Acta Physiol Scand 58, 319. 1963.
    • 450. Baker CH, O'Brien LJ. Vascular volume changes in the dog forelimb. Am J Physiol 206, 1291. 1964.
    • 451. Callahan RJ, Froelich JW, McKusick KA, Leppo J, Strauss HW. A modified method for the in vivo labeling of red blood cells with Tc- 99m: concise communication. J Nucl Med 1982;23:315-8.
    • 452. Scott-Douglas NW, Manyari DE, Smiseth OA et al. Measurement of intestinal vascular capacitance in dogs: an application of blood pool scintigraphy. J Appl Physiol 1995;78:232-8.
    • 453. Manyari DE, Rose S, Tyberg JV, Sheldon RS. Abnormal reflex venous function in patients with neuromediated syncope. J Am Coll Cardiol 1996;27:1730-5.
    • 454. Manyari DE, Malkinson TJ, Robinson V, Smith ER, Cooper KE. Acute changes in forearm venous volume and tone using radionuclide plethysmography. Am J Physiol 1988;255:H947-H952.
    • 456. Robinson BF, Collier JG, Dobbs RJ. Acquired tolerance to dilator action of hydrallazine during oral administration. Br J Clin Pharmacol 1980;9:407-12.
    • 458. Manyari DE, Smith ER, Spragg J. Isosorbide dinitrate and glyceryl trinitrate: demonstration of cross tolerance in the capacitance vessels. Am J Cardiol 1985;55:927-31.
    • 459. Saltin B. Haemodynamic adaptations to exercise. Am J Cardiol 1985;42-7.
    • 460. Christ F, Gamble J, Baschnegger H, Gartside IB. Relationship between venous pressure and tissue volume during venous congestion plethysmography in man. J Physiol 1997;503 ( Pt 2):463-7.
    • Wilkinson IB, Webb DJ. Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. Br J Clin Pharmacol 2001;52:631-46.
    • 462. Ensink FBM BDWHZJHG. The reliability of venous capacity and blood flow determination by plethysmograph. In: Jagenau AHM, ed. Non-invasive methods on cardiovascular haemodynamics. Amsterdam: Elsevier / North Holland, 1981:215-26.
    • 463. Ensink FBM HG. History and principle of strain gauge plethysmography. In: Jageneau AHM, ed. Non-invasive methods on cardiovascular haemodjmamics. Amsterdam: Elsevier / North Holland, 1981:169-83.
    • 464. Christ F, Gamble J, Gartside IB, Kox WJ. Increased microvascular water permeability in patients with septic shock, assessed with venous congestion plethysmography (VCP). Intensive Care Med 1998;24:18-27.
    • 465. Christ F, Gartside IB, Kox WJ, Gamble J. [Microvascular monitoring using mercury in silastic strain gauge plethysmography (MSG)]. Infusionsther Transfusionsmed 1993;20:253-9.
    • 467. Alexander RS, Edwards WS Ankeney JL. The distensibility characteristics of the portal vascular bed. Circ.Res. 1,271-277. 1953.
    • 468. Porciuncula Cl, Armstrong jr. GG Guyton AC Stone HL. Delayed compliance in external jugular vein of the dog. Am J Physiol 207, 728-732. 1964.
    • 469. Prather JW, Taylor AE Guyton AC. Effect of blood volume, mean circulatory pressure, and stress relaxation on cardiac output. Am J Physiol 216,467-472. 1969.
    • 470. Bevegard BS, Shepherd JT. Reaction in man of resistance and capacity vessels in forearm and hand to leg exercise. J Appl Physiol 1966;21:123-32.
    • 471. Zelis R, Capone R Mansour E Field JM. The effects of short term venous congestion on forearm venous volume and reactive hyperemia blood flow in human subjects. Circulation 57,1001-1003. 1978.
    • 472. Schmitt M, Nightingale AK, Broadley A et al. Atrial Natriuretic Peptide Regulates Venous Capacitance in Man [abstr]. Circulation 2001;104:11-393.
    • 473. Schmitt M, Taylor J, Broadley A et al. ANP but Not CNP Modulates Venous Capacitance in Chronic Heart Failure [abstr]. Eur J Heart Fail 2002; 1:87.
    • 474. Jaap AJ, Shore AC, Gartside IB, Gamble J, Tooke JE. Increased microvascular fluid permeability in young type 1 (insulin- dependent) diabetic patients. Diabetologia 1993;36:648-52.
    • 475. Brown E, Greenfield DM, Goei JS, Plassaras G. Filling and emptying of the low-pressure blood vessels of the human forearm. J Appl Physiol 1966;21:573-82.
    • 476. Forbes CD, Prentice CR. Thrombus formation and artificial surfaces. Br Med Bull 1978;34:201-7.
    • 477. Hackett E. Blood the Paramount Humour. London: Jonathan Cape, 1973.
    • Michelin Guide: Paris. London: John Murray, 1972:134.
    • 479. Anderson W.D. Thorax of Sheep and Man; an Anatomy Atlas. Minneapolis: Dillon Press, 1971.
    • 482. Charles CJ, Espiner EA, Richards AM. Cardiovascular actions of ANF: contributions of renal, neurohumoral, and hemodynamic factors in sheep. Am J Physiol 1993;264:R533-R538.
    • 483. Charles CJ, Espiner EA, Richards AM, Nicholls MG, Yandle TO. Biological actions and pharmacokinetics of C-type natriuretic peptide in conscious sheep. Am J Physiol 1995;268:R201-R207.
    • 484. Charles CJ, Espiner EA, Richards AM, Nicholls MG, Yandle TG. Comparative bioactivity of atrial, brain, and C-type natriuretic peptides in conscious sheep. Am J Physiol 1996;270:R1324-R1331.
    • 485. Charles CJ, Rademaker MT, Richards AM et al. Hemodynamic, hormonal, and renal effects of adrenomedullin in conscious sheep. Am J Physiol 1997;272:R2040-R2047.
    • 486. Fitzpatrick MA, Nicholls MG, Espiner EA, Ikram H, Bagshaw P, Yandle TG. Neurohumoral changes during onset and offset of ovine heart failure: role of ANP. Am J Physiol 1989;256:H1052-H1059.
    • 487. Fitzpatrick MA, Rademaker MT, Frampton CM et al. Hemodynamic and hormonal effects of renin inhibition in ovine heart failure. Am J Physiol 1990;258:H1625-H1631.
    • 488. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Nicholls MG, Richards AM. Comparative bioactivity of atrial and brain natriuretic peptides in an ovine model of heart failure.
    • 489. Rademaker MT, Fitzpatrick MA, Charles CJ et al. Central angiotensin II ATIreceptor antagonism in normal and heart- failed sheep. Am J Physiol 1995;269:H425-H432.
    • 490. Rademaker MT, Charles CJ, Espiner EA, Nicholls MG, Richards AM, Kosoglou T. Neutral endopeptidase inhibition: augmented atrial and brain Rapid nongenomic effects of aldosterone in the human forearm? Schmitt M, Gunamwan P, Freimeaux MP Hypertension 2003;Nov 24 [epub ahead of print].
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article